XL-protein’s proprietary PASylation® technology is patented worldwide by 7 patent families, including patents issued in Europe, the United States, Japan as well as several other countries and territories. In 2009 XL-protein acquired an exclusive license from the Technische Universität München (TUM), where the PASylation® technology was originally developed.

XL-protein’s IP portfolio ensures strong international protection for its PASylation® technology and, in particular, all drugs emerging from this half-life extension platform.

XL-protein® and PASylation® are registered trademarks of XL-protein GmbH.